Health

Oral Drug Highly Active in Rare Blood Cancers With FGFR1 Rearrangements

TribeNews
By TribeNews Add a Comment
0 Min Read
Oral Drug Highly Active in Rare Blood Cancers With FGFR1 Rearrangements

MedPage Today) — Most patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements receiving pemigatinib (Pemazyre) experienced complete responses in the phase II FIGHT-203 trial.
Among 45 patients analyzed for efficacy, the overall complete…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app